The rationale for the design begins with the tumor microenvironment itself. Immune checkpoint inhibitors have transformed outcomes for a subset of patients with non-small cell lung cancer, but durable responses remain confined to a minority, and one of the key reasons is the reversible polarization of tumor-associated macrophages. These cells, which are numerically dominant among immune infiltrates in solid tumors, tend to adopt an M2-like, immunosuppressive phenotype that dampens inflammation, promotes tissue remodeling, and shields tumor cells from cytotoxic lymphocytes. Rather than simply depleting these macrophages, the research team set out to hijack them, exploiting their phagocytic appetite and their expression of mannose receptors such as CD206 to make them take up, process, and present a tumor antigen.

The choice of antigen was equally deliberate. CLDN6 is a member of the claudin family, proteins that seal the gaps between epithelial and endothelial cells. In normal adults its expression is restricted to immune-privileged sites such as the placenta and testes, but it is re-expressed at high levels in ovarian, gastric, and lung cancers, where elevated levels correlate with shorter survival in lung adenocarcinoma. That profile makes it an attractive target for immunotherapy: a vaccine aimed at CLDN6 should generate potent anti-tumor immunity while minimizing off-target toxicity. The team engineered lung cancer cell lines to overexpress human CLDN6, confirming expression rates above 90 percent by flow cytometry before proceeding to animal studies.

Structurally, the nanovaccine is a self-assembling coordination polymer. Zinc nitrate and 2-methylimidazole crystallize in water into polyhedral ZIF-8 particles roughly 115 nanometers across, which are then coated with polyethyleneimine and mannose to yield Zn-MAN particles of about 132 nanometers. When CLDN6 is incorporated during assembly, the final Zn-MAN@CLDN6 particles grow to roughly 186 nanometers and take on a near-spherical shape with a negative surface charge. Inductively coupled plasma mass spectrometry and protein assays established the composition: the zinc scaffold accounts for about 67 percent of the mass, the mannose targeting layer about 25 percent, and the loaded CLDN6 antigen about 5 percent, with encapsulation efficiency reaching approximately 80 percent at optimal antigen concentrations.

The most elegant feature of the material is its pH responsiveness. At physiological pH 7.4, less than 20 percent of the CLDN6 cargo is released over 24 hours, protecting the antigen from nonspecific degradation in the bloodstream. But when the particles reach the acidic environment of a tumor, around pH 6.5, their edges begin to soften, and inside the lysosomes of macrophages, at pH 5, the imidazolate framework collapses entirely: zinc ion release approaches 80 percent within six hours and CLDN6 release reaches about 90 percent. Transmission electron microscopy captured this disintegration directly, showing intact spheres at neutral pH, partially disassembled particles at tumor-like acidity, and complete structural collapse under lysosomal conditions.

Once inside macrophages, the released zinc ions act as more than a delivery trigger; they function as an endogenous adjuvant. Zinc is known to amplify toll-like receptor 4 signaling, prompting macrophages to secrete inflammatory cytokines such as TNF-alpha and IL-1beta, and to upregulate the co-stimulatory molecules CD80 and CD86 that T cells require alongside antigen recognition. When the researchers chelated zinc with TPEN, the vaccine’s ability to drive M1 polarization and antigen presentation collapsed, confirming that the metal ion is not incidental but central to the immune activation. Treated macrophages showed sharply elevated expression of MHC class I and II molecules and the inflammatory cytokine IL-12, hallmarks of professional antigen-presenting cells.

Functionally, the reprogrammed macrophages became far more aggressive. Bone-marrow-derived macrophages conditioned with the vaccine engulfed tumor cells at significantly higher rates and showed a greater than sevenfold increase in tumor cell killing compared with untreated macrophages. When these educated macrophages were co-cultured with T cells, the lymphocytes responded with vigorous proliferation and copious interferon-gamma secretion, and the primed T cells subsequently killed CLDN6-expressing tumor cells with markedly enhanced efficiency, releasing granzyme B and perforin. Macrophage depletion experiments using an anti-CSF1R antibody substantially diminished the vaccine’s anti-tumor effect in mice, demonstrating that the therapeutic activity genuinely depended on macrophage targeting and reprogramming rather than any direct cytotoxicity of the particles themselves.

Single-cell RNA sequencing of treated tumors revealed the depth of the microenvironmental remodeling. In untreated mice, malignant cells dominated the tumor landscape; after vaccination, macrophages and CD8-positive T cells jointly formed the dominant population. The vaccine increased the proportion of M1-like macrophages expressing CD80, CD86, and CD40, raised antigen-presentation genes including CD74 and the MHC genes H2-Aa and H2-Ab1, and reduced the fraction of cancer cells expressing PD-L1. Cell-communication analysis identified two critical signaling axes: macrophage-derived CXCL16 engaging CXCR6 on effector CD8 T cells, which positions the killer cells within tumors, and IL-15 signaling through IL-15RA and the JAK3/STAT5 pathway, which supplies survival and proliferation signals that prevent T cell exhaustion. Blocking JAK3 pharmacologically with decernotinib impaired STAT5 phosphorylation and reduced T cell-mediated tumor killing, confirming the pathway’s importance.

The vaccine also softened the tumor’s physical defenses. Collagen I forms a dense stromal barrier that impedes T cell infiltration, and the single-cell data showed that collagen production was largely confined to tumor cells while matrix metalloproteinases came from other compartments. Zn-MAN@CLDN6 increased MMP-2 expression in cancer-associated fibroblasts while suppressing macrophage-derived MMP-9 through a zinc-dependent induction of the RNA-binding protein ZFP36L2, which represses the transcription factor BARX1. In macrophages lacking ZFP36L2, the vaccine could no longer drive M2-to-M1 repolarization, tying this transcriptional circuit directly to the therapeutic mechanism. The net effect was degradation of the collagenous matrix and improved access for cytotoxic lymphocytes to the tumor core.

In vivo, the results were striking. Three intravenous doses at weekly intervals produced the strongest tumor growth suppression of all tested regimens, with TUNEL staining revealing extensive apoptosis and Ki-67 staining showing curtailed proliferation. The effect was strictly dependent on CLDN6: efficacy was markedly reduced in wild-type tumors lacking the antigen. In a metastasis model, the vaccine inhibited the spread of tumor cells through the bloodstream, and when combined with anti-PD-1 antibody, two of five mice achieved complete tumor ablation. Importantly, the vaccine retained potent activity in humanized mice engrafted with human lung cancer cells, a critical preclinical benchmark for translation. The authors caution that challenges remain, including the variable cross-presentation capacity of different macrophage subsets, the long-term metabolic burden of zinc accumulation, and the theoretical risk of autoimmune reactions against CLDN6 in reproductive tissues. Nevertheless, the study elevates tumor-associated macrophages from passive antigen couriers to active architects of an immune-permissive microenvironment, and offers a blueprint for treating CLDN6-positive lung cancer that could extend to combination regimens with CAR-T or TCR-T cell therapies.

Subject of Research: A mannose-functionalized zinc metal-organic framework nanovaccine delivering CLDN6 antigen to reprogram tumor-associated macrophages for lung cancer immunotherapy

Article Title: A zinc organic metal skeleton vaccine for lung cancer treatment can stimulate strong innate and adaptive anti-tumor immunity

Article References: Liu, X., Zhang, X., Wang, Y., Wang, H., Mao, S., Li, M., & Liu, H. (2026). A zinc organic metal skeleton vaccine for lung cancer treatment can stimulate strong innate and adaptive anti-tumor immunity. Materials Today Bio, 41, Article 103719. https://doi.org/10.1016/j.mtbio.2026.103719

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103719

Keywords: nanovaccine, metal-organic framework, lung cancer, CLDN6, tumor-associated macrophages, macrophage reprogramming, CD8 T cells, CXCL16-CXCR6, IL-15 signaling, zinc ions, immune checkpoint blockade, tumor microenvironment